Drug Design

 

Novel methods in drug development

A robustness-based approach to systems-oriented drug design

The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease

The Connectivity Map: a new tool for biomedical research

Lab-on-a-chip: microfluidics in drug discovery

Multiplexed protein measurement: technologies and applications of protein and antibody arrays

Targeting the Cell Cycle: A New Approach to Cancer Therapy

 

Osteosarcoma Drug Development

Identification of Human Autologous Cytotoxic T-Lymphocyte-Defined Osteosarcoma Gene That Encodes a Transcriptional Regulator, Papillomavirus Binding Factor

Biology of Childhood Osteogenic Sarcoma and Potential Targets for Therapeutic Development: Meeting Summary

 

Cancer Targets

Key cancer cell signal transduction pathways as therapeutic targets

Nuclear Factor-KappaB Modulation As a Therapeutic Approach in Hematologic Malignancies

Tyrosine Kinases as Targets for Cancer Therapy

A genetic approach to inactivating chemokine receptors using a modified viral protein

In-vitro and In-vivo cytoxicity of an anti-Osteosarcoma Immunotoxin Containing Pokeweed Antiviral Protein

Phosphatidyl inositol signalling by BCR/ABL: opportunities for drug development

 

Cancer Drugs in Development

Sunitinib maleate p. 279

FDA Drug Approval Summaries: Pemetrexed (Alimta®)

Novel effect of Y-24180, a presumed specific platelet-activating factor receptor antagonist, on Ca2+ levels and growth of human osteosarcoma cells

4-Demethoxy-30-deamino-30-aziridinyl-40-methylsulphonyldaunorubicin (PNU-159548): A promising new candidate for chemotherapeutic treatment of osteosarcoma patients

Genzyme launches diagnostic to monitor gleevec resistance